ARID1A and ovarian carcinoma: We took note that a number of cell lines often used as high-grade serous models or generically as “ovarian carcinoma” had both ARID1A mutations and immuno-profiles consistent with the endometrioid type, the third most common type accounting for less than 10% of ovarian carcinomas [3], [4].